Here are just a few editorial highlights from the DDNews Cancer Research News site and other online vehicles of DDNews magazine to get you acquainted with the website and show you the range of our coverage.
 

 
By Dr. Dragan Cicic, Actinium Pharmaceuticals Inc.
Patients with blood cancers often face poor long-term survival outcomes, but a new treatment approach could offer more effective targeting of cancer cells as well as lower toxicity.
 
By Kelsey Kaustinen, DDNews Senior Editor
If all milestones are met, the agreement could be worth up to $817 million
 
By Jeffrey Bouley, DDNews Chief Editor
Multiple Myeloma Research Foundation announces six new clinical trials in 2014, and Cellectar Biosciences announces IND for relapsed or refractory multiple myeloma drug
 
By Lloyd Dunlap, DDNews Managing Editor
Service center will allow the expansion of new immunotherapy experimental platforms to advance translational medical research and the treatment of cancers
 
DDNews Cancer Research Exclusive: Turning an eye to TERT
By Kelsey Kaustinen, DDNews Senior Editor
As part of the TCGA initiative, researchers have discovered multiple cases of missing chromosomes in chromophobe renal cell carcinoma, as well as rearrangements in the promoter region of the TERT gene
 
 
 
 
 
Horizon Diagnostics, UK NEQAS announce strategic partnership
March 2012
SHARING OPTIONS:

CAMBRIDGE, U.K.—Horizon Diagnostics, a division of Horizon Discovery, and the United Kingdom National External Quality Assessment Service (UK NEQAS ICC) have announced a strategic partnership agreement for the development of genetically defined reference standards for novel lung cancer biomarkers. With the new standards, variability can be minimized in FISH- and IHC-based diagnostic testing when it comes to prescription of therapies. Per the agreement, UK NEQAS ICC will receive an exclusive license to distribute reference standards pertaining to certain lung cancer biomarkers in the U.K. and elsewhere in Europe for proficiency testing in its quality assessment program.  
 
"We look forward to seeing our genetically defined reference standards adopted in proficiency schemes and as batch controls, ultimately helping to improve the accuracy of diagnostic testing for patients," said Dr. Paul Morrill, commercial director for Horizon Discovery, in a statement.

Back







CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2014 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.